[go: up one dir, main page]

NO20073788L - Kjemiske forbindelser - Google Patents

Kjemiske forbindelser

Info

Publication number
NO20073788L
NO20073788L NO20073788A NO20073788A NO20073788L NO 20073788 L NO20073788 L NO 20073788L NO 20073788 A NO20073788 A NO 20073788A NO 20073788 A NO20073788 A NO 20073788A NO 20073788 L NO20073788 L NO 20073788L
Authority
NO
Norway
Prior art keywords
chemical connections
novel compounds
connections
chemical
cancer
Prior art date
Application number
NO20073788A
Other languages
English (en)
Norwegian (no)
Inventor
Dingwei Yu
Bin Wang
Tao Wang
Michelle Lamb
Peter Mohr
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20073788L publication Critical patent/NO20073788L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20073788A 2005-02-16 2007-07-20 Kjemiske forbindelser NO20073788L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65357505P 2005-02-16 2005-02-16
US74213805P 2005-12-01 2005-12-01
PCT/GB2006/000513 WO2006087530A1 (fr) 2005-02-16 2006-02-15 Composés chimiques

Publications (1)

Publication Number Publication Date
NO20073788L true NO20073788L (no) 2007-09-03

Family

ID=36168456

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073788A NO20073788L (no) 2005-02-16 2007-07-20 Kjemiske forbindelser

Country Status (21)

Country Link
US (2) US8129403B2 (fr)
EP (1) EP1853588B1 (fr)
JP (1) JP5001179B2 (fr)
KR (1) KR101362621B1 (fr)
AT (1) ATE398613T1 (fr)
AU (1) AU2006215386B2 (fr)
BR (1) BRPI0607455A2 (fr)
CA (1) CA2597813C (fr)
CY (1) CY1108275T1 (fr)
DE (1) DE602006001515D1 (fr)
DK (1) DK1853588T3 (fr)
ES (1) ES2308731T3 (fr)
IL (1) IL185063A (fr)
MX (1) MX2007009843A (fr)
NO (1) NO20073788L (fr)
NZ (1) NZ561525A (fr)
PL (1) PL1853588T3 (fr)
PT (1) PT1853588E (fr)
RU (1) RU2405780C2 (fr)
SI (1) SI1853588T1 (fr)
WO (1) WO2006087530A1 (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0104140D0 (sv) * 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
PT1846394E (pt) * 2005-02-04 2012-01-05 Astrazeneca Ab Derivados de pirazolilaminopiridina úteis como inibidores da quinase
ES2308731T3 (es) 2005-02-16 2008-12-01 Astrazeneca Ab Compuestos quimicos.
AU2006248780B2 (en) * 2005-05-16 2010-06-03 Astrazeneca Ab Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
WO2007049041A1 (fr) * 2005-10-28 2007-05-03 Astrazeneca Ab Derives 4-(3-aminopyrazole)pyrimidine et leur utilisation en tant qu’inhibiteurs de tyrosine kinases dans le cadre d’un traitement anticancereux
US7767685B2 (en) * 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
ES2383370T3 (es) 2006-10-19 2012-06-20 Signal Pharmaceuticals Llc Compuestos de heteroarilo, sus composiciones y uso de los mismos como inhibidores de proteína quinasa
JP2010507581A (ja) * 2006-10-20 2010-03-11 ナームローゼ・フエンノートチヤツプ・オルガノン ＰＫＣ−θ阻害薬としてのプリン類
CN101679429A (zh) * 2007-04-18 2010-03-24 阿斯利康(瑞典)有限公司 5-氨基吡唑-3-基-3h-咪唑并[4,5-b]吡啶衍生物及其治疗癌的用途
UA99459C2 (en) * 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
GB0725218D0 (en) * 2007-12-24 2008-02-06 Syngenta Ltd Chemical compounds
AU2009259026B2 (en) * 2008-06-11 2012-10-04 Astrazeneca Ab Tricyclic 2,4-diamin0-L,3,5-triazine derivatives useful for the treatment of cancer and myeloproliferative disorders
KR20110071098A (ko) * 2008-09-30 2011-06-28 아스트라제네카 아베 복소환 ｊａｋ 키나제 억제제
PA8851101A1 (es) 2008-12-16 2010-07-27 Lilly Co Eli Compuesto amino pirazol
JP2013508456A (ja) 2009-10-26 2013-03-07 シグナル ファーマシューティカルズ， エルエルシー ヘテロアリール化合物の合成方法および精製方法
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
WO2011133920A1 (fr) 2010-04-23 2011-10-27 Cytokinetics, Inc. Aminopyridines et aminotriazines, leurs compositions et leurs procédés d'utilisation
AR081331A1 (es) * 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
WO2012097478A1 (fr) * 2011-01-21 2012-07-26 Abbott Laboratories Inhibiteurs de kinase à base de carboxamide bicyclique
SG10201912850WA (en) 2011-10-19 2020-02-27 Signal Pharm Llc Treatment Of Cancer With TOR Kinase Inhibitors
ES2694413T3 (es) 2011-12-02 2018-12-20 Signal Pharmaceuticals, Llc Composiciones farmacéuticas de 7-(6-(2-hidroxipropan-2-il)piridin-3-il)-1-((trans)-4-metoxiciclohexil)-3,4-dihidropirazino [2,3-b]pirazin-2(1H)-ona, una forma sólida de la misma y métodos para su uso
CA2864905A1 (fr) 2012-02-24 2013-08-29 Signal Pharmaceuticals, Llc Procedes de traitement du cancer du poumon sans petites cellules a l'aide d'une therapie combinee d'inhibiteur de kinase
SG11201405761WA (en) 2012-03-16 2014-10-30 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors
TWI585088B (zh) 2012-06-04 2017-06-01 第一三共股份有限公司 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物
WO2013188184A1 (fr) 2012-06-14 2013-12-19 Eli Lilly And Company Inhibiteur de jak1 et jak2
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
EP2945636B1 (fr) 2013-01-16 2017-06-28 Signal Pharmaceuticals, LLC Composés de type pyrrolopyrimidine substituée, compositions en contenant et méthodes de traitement faisant appel à eux
CN105026398B (zh) * 2013-03-05 2018-05-18 默克专利股份公司 用于治疗疾病诸如癌症的三唑并[4,5-d]嘧啶衍生物
US9370515B2 (en) 2013-03-07 2016-06-21 Califia Bio, Inc. Mixed lineage kinase inhibitors and method of treatments
AU2014254057A1 (en) 2013-04-17 2015-11-05 Signal Pharmaceuticals, Llc Combination therapy comprising a TOR kinase inhibitor and N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
MX368286B (es) 2013-04-17 2019-09-27 Signal Pharm Llc Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
BR112015026257B1 (pt) 2013-04-17 2022-12-20 Signal Pharmaceuticals, Llc Uso de um composto dihidropirazino-pirazina e enzalutamida, composição farmacêutica que os compreende, e kit
ES2944478T3 (es) 2013-04-17 2023-06-21 Signal Pharm Llc 1-etil-7-(2-metil-6-(1H-1,2,4-triazol-3-il)piridin-3-il)-3,4-dihidropirazino[2,3-b]pirazin-2(1H)-ona para tratar el glioblastoma multiforme
SG11201508527VA (en) 2013-04-17 2015-11-27 Signal Pharm Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
KR102242505B1 (ko) 2013-04-17 2021-04-20 시그날 파마소티칼 엘엘씨 암 치료용 tor 키나제 억제제 및 시티딘 유사체를 포함하는 병용 요법
NZ629411A (en) 2013-04-17 2017-06-30 Signal Pharm Llc Treatment of cancer with dihydropyrazino-pyrazines
JP6401250B2 (ja) 2013-05-29 2018-10-10 シグナル ファーマシューティカルズ，エルエルシー ７−（６−（２−ヒドロキシプロパン−２−イル）ピリジン−３−イル）−１−（（ｔｒａｎｓ）−４−メトキシシクロヘキシル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オン、その固体形態の医薬組成物、及びその使用方法
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
TWI663159B (zh) 2013-12-10 2019-06-21 美商健臻公司 原肌球蛋白相關之激酶（ｔｒｋ）抑制劑
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
US9718824B2 (en) 2014-04-16 2017-08-01 Signal Pharmaceuticals, Llc Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
US9512129B2 (en) 2014-04-16 2016-12-06 Signal Pharmaceuticals, Llc Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
US9737535B2 (en) 2014-04-16 2017-08-22 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines
AU2015289929A1 (en) 2014-07-14 2017-03-02 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
MY195799A (en) 2014-12-18 2023-02-21 Genzyme Corp Pharmaceutical Formulations of Tropomyosin-Related Kinase (TRK) Inhibitors
HUE049801T2 (hu) 2014-12-23 2020-10-28 Sma Therapeutics Inc 3,5-diaminopirazol kináz inhibitorok
EP3641772B1 (fr) 2017-06-22 2023-08-02 Celgene Corporation Traitement du carcinome hépatocellulaire caractérisé par une infection par le virus de l'hépatite b
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1417402A (en) 1972-03-30 1975-12-10 Boots Co Ltd Pharmacologically active anilinobenzothiazoles
DE2426180A1 (de) 1974-05-29 1975-12-18 Bayer Ag Verfahren zum faerben von polyurethankunststoffen
US4485284A (en) * 1982-01-11 1984-11-27 Advanced Moisture Technology, Inc. Apparatus and process for microwave moisture analysis
US5006116A (en) 1988-12-21 1991-04-09 Kimberly-Clark Corporation Tampon with single layer powder bonded wrap
HU206337B (en) 1988-12-29 1992-10-28 Mitsui Petrochemical Ind Process for producing pyrimidine derivatives and pharmaceutical compositions
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
CA2104053C (fr) * 1992-08-31 1999-04-13 Miguel A. Cacho Procede automatique a lit fluidise
US5543520A (en) 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
WO1997009325A1 (fr) 1995-09-01 1997-03-13 Signal Pharmaceuticals, Inc. Carboxylates de pyrimidine, composes connexes et methodes de traitement des etats inflammatoires
US5935966A (en) 1995-09-01 1999-08-10 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
US5753635A (en) * 1996-08-16 1998-05-19 Berlex Laboratories, Inc. Purine derivatives and their use as anti-coagulants
DK0970369T3 (da) * 1997-03-27 2002-01-28 Glatt Gmbh Fremgangsmåde til overvågning og/eller styring og regulering af en granulerings-, agglomererings-, instantiserings-, coating- og tørringsproces i en fluid bed eller bevæget .....
CA2321153A1 (fr) 1998-02-17 1999-08-19 Timothy D. Cushing Antiviraux derives de pyrimidine
US6247246B1 (en) * 1998-05-27 2001-06-19 Denver Instrument Company Microwave moisture analyzer: apparatus and method
AU5438299A (en) 1998-08-29 2000-03-21 Astrazeneca Ab Pyrimidine compounds
WO2000014552A1 (fr) 1998-09-03 2000-03-16 Malcam Ltd. Dispositif servant a mesurer l'humidite au moyen de micro-ondes
US6227041B1 (en) 1998-09-17 2001-05-08 Cem Corporation Method and apparatus for measuring volatile content
AU762523C (en) 1998-11-10 2004-02-12 Janssen Pharmaceutica N.V. HIV replication inhibiting pyrimidines
WO2000035455A1 (fr) 1998-12-15 2000-06-22 Telik, Inc. Urees heteroaryle-aryle utilisees comme antagonistes du recepteur igf-1
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
DE19917785A1 (de) 1999-04-20 2000-10-26 Bayer Ag 2,4-Diamino-pyrimidin-Derivate
IT1306704B1 (it) 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
EP1206265B1 (fr) * 1999-06-30 2003-11-12 Merck & Co., Inc. Composes inhibiteurs de la src kinase
US6399780B1 (en) * 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
ATE309241T1 (de) 1999-09-10 2005-11-15 Merck & Co Inc Tyrosin kinase inhibitoren
KR100820605B1 (ko) 1999-09-24 2008-04-08 얀센 파마슈티카 엔.브이. 항바이러스 조성물
US6455525B1 (en) * 1999-11-04 2002-09-24 Cephalon, Inc. Heterocyclic substituted pyrazolones
DE60043397D1 (de) 1999-12-28 2010-01-07 Pharmacopeia Inc Cytokine, insbesondere tnf-alpha, hemmer
AU2001237041B9 (en) 2000-02-17 2005-07-28 Amgen Inc. Kinase inhibitors
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
US7034019B2 (en) 2000-05-08 2006-04-25 Janssen Pharmaceutica N.V. Prodrugs of HIV replication inhibiting pyrimidines
CZ2003468A3 (cs) 2000-08-31 2004-05-12 Pfizeráproductsáinc Deriváty pyrazolu a jejich použití jako inhibitorů proteinkinázy
US7071217B2 (en) 2000-09-01 2006-07-04 Smithkline Beecham Corporation Substituted oxindole derivatives as tyrosine kinase inhibitors
EP1317446A1 (fr) 2000-09-01 2003-06-11 Glaxo Group Limited Derives d'oxindole
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
AU2001296871A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) * 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6610677B2 (en) * 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6613776B2 (en) * 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
HUP0400639A3 (en) 2000-12-21 2010-03-29 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
WO2003011855A2 (fr) * 2001-08-03 2003-02-13 Vertex Pharmaceuticals Incorporated Inhibiteurs de kinase derives du pyrazole et leurs utilisations
CA2456187A1 (fr) * 2001-08-03 2003-02-13 Qing Tang Inhibiteurs de kinase derives du pyrazole et leurs utilisations
WO2003026666A1 (fr) 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation Derives de 2-phenylamino-4- (5-pyrazolylamino)-pyrimidine utilises comme inhibiteurs de la kinase, en particulier comme inhibiteurs de la kinase src
JP2005508337A (ja) 2001-09-27 2005-03-31 スミスクライン ビーチャム コーポレーション 化合物
US6747461B2 (en) * 2001-10-25 2004-06-08 Pioneer Hi-Bred International, Inc. Apparatus and method for monitoring drying of an agricultural porous medium such as grain or seed
SE0104140D0 (sv) 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
JP2007052466A (ja) 2003-11-17 2007-03-01 Nec Corp 画像処理方法、画像処理システム、および画像処理プログラム
WO2005095400A1 (fr) 2004-03-30 2005-10-13 Vertex Pharmaceuticals Incorporated Azaindoles utiles comme inhibiteurs de janus kinases et d'autres proteines kinases
JP2007533717A (ja) * 2004-04-21 2007-11-22 アストラゼネカ アクチボラグ 化合物
US7528138B2 (en) * 2004-11-04 2009-05-05 Vertex Pharmaceuticals Incorporated Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
DE102004053734B4 (de) 2004-11-06 2007-01-18 Sartorius Ag Trocknungswaage
PT1846394E (pt) 2005-02-04 2012-01-05 Astrazeneca Ab Derivados de pirazolilaminopiridina úteis como inibidores da quinase
ES2308731T3 (es) 2005-02-16 2008-12-01 Astrazeneca Ab Compuestos quimicos.
AU2006215394B2 (en) 2005-02-16 2009-10-08 Astrazeneca Ab Chemical compounds
WO2006115452A1 (fr) 2005-04-27 2006-11-02 Astrazeneca Ab Utilisation des derives de la pyrazolyl-pyrimidine dans le traitement de la douleur
WO2006118231A1 (fr) 2005-04-28 2006-11-09 Mitsubishi Tanabe Pharma Corporation Dérivé de cyanopyridine et emploi dudit dérivé au titre de médicament
JP2008540391A (ja) * 2005-05-05 2008-11-20 アストラゼネカ アクチボラグ ピラゾリルアミノ置換ピリミジン、および癌の処置におけるそれらの使用
AU2006248780B2 (en) 2005-05-16 2010-06-03 Astrazeneca Ab Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
WO2007049041A1 (fr) 2005-10-28 2007-05-03 Astrazeneca Ab Derives 4-(3-aminopyrazole)pyrimidine et leur utilisation en tant qu’inhibiteurs de tyrosine kinases dans le cadre d’un traitement anticancereux
CN101316597B (zh) * 2005-11-03 2013-04-17 顶点医药品公司 用作激酶抑制剂的氨基嘧啶
UY30444A1 (es) * 2006-06-30 2008-01-31 Astrazeneca Ab Derivados de pirimidina, procesos para su preparacinn, composiciones farmaccuticos y usos de los mismos.
TW200823196A (en) * 2006-11-01 2008-06-01 Astrazeneca Ab New use
TW200826937A (en) * 2006-11-01 2008-07-01 Astrazeneca Ab New use

Also Published As

Publication number Publication date
CY1108275T1 (el) 2014-02-12
DK1853588T3 (da) 2008-09-15
RU2007134396A (ru) 2009-03-27
NZ561525A (en) 2010-11-26
KR101362621B1 (ko) 2014-02-13
PT1853588E (pt) 2008-08-25
JP2008530190A (ja) 2008-08-07
BRPI0607455A2 (pt) 2009-09-01
HK1114375A1 (en) 2008-10-31
JP5001179B2 (ja) 2012-08-15
SI1853588T1 (sl) 2008-10-31
MX2007009843A (es) 2007-08-23
KR20070103773A (ko) 2007-10-24
WO2006087530A1 (fr) 2006-08-24
CA2597813C (fr) 2014-04-22
RU2405780C2 (ru) 2010-12-10
DE602006001515D1 (de) 2008-07-31
US20080176872A1 (en) 2008-07-24
EP1853588A1 (fr) 2007-11-14
US20120122892A1 (en) 2012-05-17
US8129403B2 (en) 2012-03-06
IL185063A0 (en) 2007-12-03
ES2308731T3 (es) 2008-12-01
IL185063A (en) 2012-01-31
AU2006215386A1 (en) 2006-08-24
CA2597813A1 (fr) 2006-08-24
EP1853588B1 (fr) 2008-06-18
ATE398613T1 (de) 2008-07-15
PL1853588T3 (pl) 2008-11-28
AU2006215386B2 (en) 2009-06-11

Similar Documents

Publication Publication Date Title
NO20073790L (no) Kjemiske forbindelser
NO20073788L (no) Kjemiske forbindelser
TW200716606A (en) Chemical compounds
TW200800963A (en) Chemical compounds
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
EA200970156A1 (ru) Пиридизиноновые производные
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
EA201690265A2 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
EA200802050A1 (ru) Новые гетероарилзамещенные ариламинопиридиновые производные в качестве мек ингибиторов
EA200801997A1 (ru) Новые соединения
SE0301700D0 (sv) Novel compounds
EA200700225A1 (ru) Аналоги тетрапептида
EA201170832A1 (ru) Пуриновые соединения
EA200801362A1 (ru) Пиримидинил бензотиофеновые соединения
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
EA201000895A1 (ru) Композиции и способы для лечения лизосомных болезней
EA201170344A1 (ru) Азаиндольные ингибиторы iap
TW200738659A (en) Novel compounds
TW200616977A (en) Enantiomers of selected fused heterocyclics and uses thereof
ATE474574T1 (de) Imidazoazephinonverbindungen
TW200621260A (en) Selected fused heterocyclics and uses thereof
NO20083352L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
EA200702590A1 (ru) Ингибиторы растворимой аденилатциклазы
DK1687301T3 (da) Thiaepothilone til behandling af kræftsygdomme

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application